Article in Molecular pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Kisa TamamuraGraduate School of Medical Sciences, Kanazawa University, Kanazawa, Ishikawa 920-1192, Japan.
Yuito AkitaGraduate School of Medical Sciences, Kanazawa University, Kanazawa, Ishikawa 920-1192, Japan.
Kenji MishiroGraduate School of Medical Sciences, Kanazawa University, Kanazawa, Ishikawa 920-1192, Japan.ORCID 0000-0002-5071-7574
Masayuki MunekaneGraduate School of Medical Sciences, Kanazawa University, Kanazawa, Ishikawa 920-1192, Japan.
Takeshi FuchigamiGraduate School of Medical Sciences, Kanazawa University, Kanazawa, Ishikawa 920-1192, Japan.ORCID 0000-0001-8141-1212
Yoshiki FujikawaDepartment of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569-8686, Japan.
Hiroshi WakabayashiDepartment of Nuclear Medicine, Kanazawa University Hospital, Kanazawa University, Takara-machi 13-1, Kanazawa, Ishikawa 920-8641, Japan.
Fuko IkomaGraduate School of Medical Sciences, Kanazawa University, Kanazawa, Ishikawa 920-1192, Japan.
Xiaojun HuCenter for Molecular Recognition and Biosensing, School of Life Sciences, Shanghai University, Shanghai 200444, China.ORCID 0000-0001-6188-4039
Shinji KawabataDepartment of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569-8686, Japan.ORCID 0000-0001-5007-5279
Seigo KinuyaDepartment of Nuclear Medicine, Kanazawa University Hospital, Kanazawa University, Takara-machi 13-1, Kanazawa, Ishikawa 920-8641, Japan.
Minoru SuzukiInstitute for Integrated Radiation and Nuclear Science, Kyoto University, Kumatori, Osaka 590-0494, Japan.ORCID 0000-0002-5421-9417
Kazuma OgawaGraduate School of Medical Sciences, Kanazawa University, Kanazawa, Ishikawa 920-1192, Japan.ORCID 0000-0002-1691-7302
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Boron neutron capture therapy (BNCT) is one of the promising cancer treatment methods with
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Development of a Theranostic Agent for Bone Metastases: Integration of Nuclear Medicine Imaging and Boron Neutron Capture Therapy (BNCT). · full record | OpenQuestion